Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit
23 5월 2023 - 1:00AM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced the first
commercial shipment of its BioXp® Select DNA Cloning kit. The
BioXp® Select DNA Cloning kit enables on-demand and automated
assembly of DNA fragments via Gibson Assembly® or Golden Gate
assembly cloning methods beginning from the customer’s linear DNA.
The continued expansion of automation capabilities of the BioXp®
platform that enable researchers to build DNA and mRNA constructs
beginning with linear DNA or plasmid DNA input is expected to
further empower researchers to optimize and accelerate their
discovery workflows. By providing researchers greater workflow
flexibility and automated options to build their DNA or mRNA
constructs, they can overcome current bottlenecks created by long
synthesis lead times and streamline their design-build-test
workflows. Thus, creating efficiencies and accelerating their
discovery process.
“The principle of RNAimmune's proprietary technology is the use
of mRNA as a data carrier to instruct the human body to produce its
own proteins capable of fighting a wide range of diseases. Our
research focuses on optimizing the mRNA molecule for delivery,
function, and other key characteristics and requires rapid analysis
and iteration. The BioXp® System is a key part of our process,
enabling us to reduce timelines, eliminate manual steps, and more
broadly test and iterate. We expect the new Select DNA Cloning kit
to be of great value in our candidate optimization and screening
workflows for mRNA vaccines,” said Dong Shen, M.D., Ph.D., Founder
and President of RNAimmune.
“The BioXp® Select kit line expands the utility of the system by
enabling researchers to begin from existing linear DNA or plasmid
DNA. This is our fourth release in 2023, and throughout the year we
plan additional releases for DNA and mRNA synthesis beginning from
the customer’s sequence, linear DNA, or plasmid DNA, and to expand
the BioXp® system to automate NGS Library Preparation thereby
providing many customers with a more complete solution for many DNA
and mRNA applications,” said Todd R. Nelson, Ph.D., CEO and Founder
of Telesis Bio. “We believe our BioXp® system can empower
researchers to accelerate their breakthrough discoveries. The
BioXp® System has the potential to significantly reduce timelines,
manual steps, and costs for constructing synthetic DNA and RNA for
numerous downstream applications including vaccine development,
therapeutics development, diagnostics, precision medicine, and DNA
data storage,” continued Todd R. Nelson.
For more information on BioXp® Select DNA Cloning Kit
please visit:
https://telesisbio.com/products/bioxp-kits/dna-cloning/
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® systems consolidate, automate,
and optimize the entire synthesis, cloning and amplification
workflow. As a result, they deliver virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
About RNAimmune
RNAimmune is an international biopharmaceutical company focusing
on mRNA vaccine and therapeutics development. Its global
headquarter is in Germantown, Maryland, USA, while the China
headquarter is located in International BioIsland, Guangzhou.
RNAimmune has received a global exclusive right to the proprietary
Polypeptide Lipid Nanoparticle (PLNP) technology for mRNA delivery
from Sirnaomics. In addition, RNAimmune has various independent
proprietary R&D platforms, including artificial-intelligence
and directed neoantigen prediction, ALEPVA algorithm for nucleic
acid sequence design and lipid nanoparticle (LNP) carrier systems.
RNAimmune also deployed various vaccines and therapeutics
pipelines, including vaccines for infectious diseases (COVID-19,
influenza, VZV and RSV etc.) and cancer vaccines (RAS, NY-ESO-1),
and protein replacement medication. RNAimmune has extremely high
potential and has become one of the leading companies in the field
of mRNA vaccines and therapeutics. Learn more at:
www.rnaimmune.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These statements include statements and guidance regarding
Telesis Bio’s future financial performance as well as statements
regarding the future release and success of new and existing
products and services. Such statements are based on current
assumptions that involve risks and uncertainties that could cause
actual outcomes and results to differ materially. These risks and
uncertainties, many of which are beyond our control, include risks
described in the section entitled Risk Factors and elsewhere in our
Quarterly Report on Form 10-Q, which was filed with the Securities
and Exchange Commission on May 12, 2023. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Telesis Bio disclaims any obligation to update
these forward-looking statements.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Telesis Bio (NASDAQ:TBIO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Telesis Bio (NASDAQ:TBIO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024